本文選題：單克隆免疫球蛋白 + 腎臟損害　； 參考：《腎臟病與透析腎移植雜志》2016年06期

【摘要】：單克隆免疫球蛋白(MIg)或其片段導(dǎo)致的腎臟損害,稱為單克隆免疫球蛋白相關(guān)腎損害(MGRS)。過去,由于MGRS血液學(xué)改變更接近意義未明的單克隆免疫球蛋白病(MGUS),不主張對除AL淀粉樣變性以外的MGRS進(jìn)行治療。但成功清除分泌MIg的細(xì)胞克隆能夠保護(hù)腎功能,進(jìn)展至終末期腎病的MGRS患者體內(nèi)MIg水平與腎移植術(shù)后MGRS復(fù)發(fā)有關(guān),獲得血液學(xué)完全緩解能夠避免移植腎失功,這些研究結(jié)果均表明MGRS并非意義未明,而必須積極治療。本文主要就MGRS診斷及治療的研究進(jìn)展加以綜述。
[Abstract]:The renal damage caused by monoclonal immunoglobulin (Mi) or its fragments is called monoclonal immunoglobulin associated renal damage (MGRSs). In the past, because the MGRS hematologic changes were closer to the unknown monoclonal immunoglobulin disease, MGRS was not treated except for AL amyloidosis. However, the successful clearance of MIg secreting cell clones can protect renal function. The level of MIg in MGRS patients who progress to end-stage nephropathy is related to the recurrence of MGRS after renal transplantation. A complete remission of hematology can avoid renal allograft dysfunction. These results suggest that MGRS is not unknown, but must be actively treated. This article reviews the progress in the diagnosis and treatment of MGRS.
【作者單位】： 南京軍區(qū)南京總醫(yī)院腎臟科國家腎臟疾病臨床醫(yī)學(xué)研究中心全軍腎臟病研究所;
【基金】：國家科技支撐計劃課題(2015BAI12B05) 第一批國家臨床重點(diǎn)�？祈椖�(2014ZDZK001)
【分類號】：R692
，

本文編號：1876942